Moreover, pharmacological inhibition of PKCα inhibits the growth of xenografts derived from triple-negative breast cancer patients, which express high PKCα levels, but also selectively target cells that have undergone EMT, which are also enriched for stem cell properties (48). This evidence concerns the gene PRKCA and triple-negative breast carcinoma.